Thursday 16 October, 2025
Objectives: The introduction of novel anti-tuberculosis drugs e.g. bedaquiline (BDQ), delamanid (DLM), and pretomanid, has revolutionized the treatment of drug-resistant…
Read morePoster: Drug/Disease Modelling - Infection
Pemba Island, Tanzania, versus Côte d’Ivoire – Population effect on apparent clearance of active albendazole metabolites
Thursday 16 October, 2025
Introduction: Soil transmitted helminth infections affect an estimated 24% of the world’s population [1]. Communities with poor access to sanitation and…
Read moreEvaluation of QT Prolongation During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
Thursday 16 October, 2025
Introduction: M2, the main metabolite of bedaquiline (BDQ), is associated with QTc prolongation. Assessing QT liabilities in persons with active…
Read moreOptimal longitudinal QT interval correction method considering changes in heart rate variability in patients treated for drug-resistant tuberculosis
Thursday 16 October, 2025
Objective: Active tuberculosis (TB) is associated with tachycardia which generally diminishes with treatment. As the typical heart rate (HR) in a…
Read moreA circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with chronic hepatitis D
Thursday 16 October, 2025
Objectives: Chronic hepatitis D (CHD) is a rare inflammatory liver disease caused by hepatitis delta virus (HDV). It is the…
Read moreTranslational pharmacokinetic-pharmacodynamic (PKPD) modelling of apramycin to facilitate prediction of efficacious dose in urinary tract infections
Thursday 16 October, 2025
Objectives: Apramycin (EBL-1003) is a broad-spectrum aminoglycoside antibiotic for the treatment of gram-negative bacteria infections that is currently under development for…
Read moreIn vitro pharmacokinetic/pharmacodynamic interaction model assessing the synergy between meropenem and fosfomycin in a clinical multi-resistant K. pneumoniae isolate.
Thursday 16 October, 2025
Objectives: Antimicrobial combination therapy offers an option for increasing efficacy and prevention against the emergence of resistance. Synergy between meropenem (MER)…
Read moreA pharmacometric model assessing the synergistic effect of bacteriophage-polymyxin combination therapy in a clinical multidrug-resistant K. pneumoniae isolate in vitro.
Thursday 16 October, 2025
Objectives: Emerging resistance to last-line antibiotics in multidrug-resistant K. pneumoniae has led to exploration of phage therapy as promising, non-traditional alternative. However,…
Read moreOptimization of dosing strategy for vancomycin using a population pharmacokinetic model combined with machine learning approaches
Thursday 16 October, 2025
Objectives: The optimized dose and frequency of dosing for vancomycin are critical to achieve target AUC and trough concentrations at…
Read morePopulation Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients
Thursday 16 October, 2025
Objectives: Introduction: Methicillin-resistant staphylococcus aureus (MRSA) infections are one of the leading causes of pulmonary exacerbations (PEx) in persons with…
Read more